BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27203676)

  • 1. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma.
    Zhou J; Wen Q; Li SF; Zhang YF; Gao N; Tian X; Fang Y; Gao J; Cui MZ; He XP; Jia LJ; Jin H; Qiao HL
    Oncotarget; 2016 Aug; 7(31):50612-50623. PubMed ID: 27203676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer.
    Silvestri L; Sonzogni L; De Silvestri A; Gritti C; Foti L; Zavaglia C; Leveri M; Cividini A; Mondelli MU; Civardi E; Silini EM
    Int J Cancer; 2003 Apr; 104(3):310-7. PubMed ID: 12569554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma.
    Mochizuki J; Murakami S; Sanjo A; Takagi I; Akizuki S; Ohnishi A
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1191-7. PubMed ID: 16048566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
    Derks M; Fowler S; Kuhlmann O
    Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of eurycomanone on cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4 in vitro.
    Pan Y; Tiong KH; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Ong CE
    J Nat Med; 2014 Apr; 68(2):402-6. PubMed ID: 23881640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
    Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
    Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population.
    Imaizumi T; Higaki Y; Hara M; Sakamoto T; Horita M; Mizuta T; Eguchi Y; Yasutake T; Ozaki I; Yamamoto K; Onohara S; Kawazoe S; Shigematsu H; Koizumi S; Kudo S; Tanaka K
    Carcinogenesis; 2009 Oct; 30(10):1729-34. PubMed ID: 19643819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Radix Astragali and Radix Rehmanniae, the components of an anti-diabetic foot ulcer herbal formula, on metabolism of model CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 probe substrates in pooled human liver microsomes and specific CYP isoforms.
    Or PM; Lam FF; Kwan YW; Cho CH; Lau CP; Yu H; Lin G; Lau CB; Fung KP; Leung PC; Yeung JH
    Phytomedicine; 2012 Apr; 19(6):535-44. PubMed ID: 22261394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
    Han SY; Zhao HY; Zhou N; Zhou F; Li PP
    J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
    Muschler E; Lal J; Jetter A; Rattay A; Zanger U; Zadoyan G; Fuhr U; Kirchheiner J
    Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices.
    Renwick AB; Watts PS; Edwards RJ; Barton PT; Guyonnet I; Price RJ; Tredger JM; Pelkonen O; Boobis AR; Lake BG
    Drug Metab Dispos; 2000 Oct; 28(10):1202-9. PubMed ID: 10997941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
    Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
    J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
    Tanaka E; Kurata N; Yasuhara H
    J Clin Pharm Ther; 2003 Jun; 28(3):157-65. PubMed ID: 12795773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.
    Robertson P; DeCory HH; Madan A; Parkinson A
    Drug Metab Dispos; 2000 Jun; 28(6):664-71. PubMed ID: 10820139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
    Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
    J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes.
    Hamitouche S; Poupon J; Dreano Y; Amet Y; Lucas D
    Toxicol Lett; 2006 Dec; 167(3):221-30. PubMed ID: 17084997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma.
    Tsunedomi R; Iizuka N; Hamamoto Y; Uchimura S; Miyamoto T; Tamesa T; Okada T; Takemoto N; Takashima M; Sakamoto K; Hamada K; Yamada-Okabe H; Oka M
    Int J Oncol; 2005 Sep; 27(3):661-7. PubMed ID: 16077914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
    Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP
    Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
    Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
    Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.